paroxysmal nocturnal hemoglobinuria pnh rare lifethreatening disease blood characterized destruction red blood cells complement system part bodys innate immune system destructive process occurs due deficiency red blood cell surface protein daf normally inhibits immune reactions since complement cascade attacks red blood cells within blood vessels circulatory system red blood cell destruction hemolysis considered intravascular hemolytic anemia ongoing research key features disease high incidence venous blood clot research suggests pnh thrombosis blood clot caused absence gpianchored complement regulatory proteins pnh platelets excessive consumption nitric oxide pnh hemolytic anemia caused acquired rather inherited intrinsic defect cell membrane deficiency glycophosphatidylinositol gpi leading absence protective exterior surface proteins normally attach via gpi may develop primary pnh context bone marrow disorders aplastic anemia secondary pnh minority affected people telltale red urine morning originally gave condition allogeneic bone marrow transplantation cure significant rates additional medical problems monoclonal antibody eculizumab reduces need blood transfusions improves quality life affected eculizumab dramatically alters natural course pnh reducing symptoms disease complications well improving survival extent may equivalent general eculizumab costs least single year treatment reported one worlds expensive classic sign pnh red discoloration urine due presence hemoglobin hemosiderin breakdown red blood urine concentrated morning color pronounced phenomenon mainly occurs primary form pnh notice point disease course remainder mainly experience symptoms anemia fatigue shortness breath small proportion patients report attacks abdominal pain difficulty swallowing pain swallowing well erectile dysfunction men occurs mainly breakdown red blood cells rapid attributable spasm smooth muscle due depletion nitric oxide red cell breakdown forty percent people pnh develop thrombosis point illness main cause severe complications death pnh may develop common sites deep vein thrombosis leg resultant pulmonary embolism clots break enter lungs pnh blood clots may also form unusual sites hepatic vein causing buddchiari syndrome portal vein liver causing portal vein thrombosis superior inferior mesenteric vein causing mesenteric ischemia veins skin cerebral venous thrombosis uncommon form stroke common cells proteins attached membranes often serving mode communication signaling cell surrounding environment signaling proteins physically attached cell membrane various ways commonly anchored glycolipids glycosyl phosphatidylinositols gpi pnh occurs result defect assembling glycolipidprotein structures surface blood common defective enzyme pnh phosphatidylinositol glycan piga one several enzymes needed make gpi gene codes piga located x chromosome males single x chromosome females one silenced xinactivation one active copy gene piga present cell regardless mutation piga gene lead absence gpi anchors expressed cell membrane mutation occurs hematopoietic stem cell bone marrow cells produces also several proteins anchor gpi cell membrane used protect cell destruction complement system without anchors cells easily targeted complement although red blood cells white blood cells platelets targeted complement red blood cells particularly vulnerable complement system part innate immune system variety functions destroying invading microorganisms opsonization direct destabilization membrane attack complex main proteins protect blood cells destruction decayaccelerating factor disrupts formation protectin binds membrane attack complex prevents binding symptoms esophageal spasm erectile dysfunction abdominal pain attributed fact hemoglobin released hemolysis binds circulating nitric oxide substance needed relax smooth muscle theory supported fact symptoms improve administration nitrates sildenafil viagra improves effect nitric oxide muscle suspicion chronic hemolysis causing chronically depleted nitric oxide may lead development pulmonary hypertension increased pressure blood vessels supplying lung turn puts strain heart causes heart historically role sleep night disease nocturnal component name attributed acidification blood night due relative hypoventilation accumulation carbon dioxide blood sleep hypothesis questioned researchers note pnh increased hemolysis sleep uncertain important role sleep actually plays blood tests pnh show changes consistent intravascular hemolytic anemia low hemoglobin raised lactate dehydrogenase raised bilirubin breakdown product hemoglobin decreased levels haptoglobin raised reticulocytes immature red cells released bone marrow replace destroyed cells concurrent problem production red cells iron deficiency direct antiglobulin test dat direct coombs test negative hemolysis pnh caused pnh occurs setting known suspected aplastic anemia abnormal white blood cell counts decreased platelet counts may seen case anemia may caused insufficient red blood cell production addition historically sucrose lysis test patients red blood cells placed lowionicstrength solution observed hemolysis used screening positive hams acid hemolysis test dr thomas ham described test performed ham test involves placing red blood cells mild acid positive result increased rbc fragility indicates pnh congenital dyserythropoietic anemia obsolete test diagnosing pnh due low sensitivity specificitycitation needed today gold standard flow cytometry white red blood cells based levels cell proteins erythrocytes may classified type ii iii pnh cells type cells normal levels type ii reduced levels type iii absent fluoresceinlabeled proaerolysin flaer test used frequently diagnose pnh flaer binds selectively glycophosphatidylinositol anchor accurate demonstrating deficit simply pnh classified context several groups screening pnh undertaken include patients unexplained thrombosis young thrombosis unusual site eg intraabdominal veins cerebral veins dermal veins evidence hemolysis eg raised ldh low red blood cell white blood cell platelet diagnosis aplastic anemia screened disagreement whether steroids prednisolone decrease severity hemolytic crises transfusion therapy may needed addition correcting significant anemia suppresses production pnh cells bone marrow indirectly severity hemolysis iron deficiency develops time due losses urine may treated present iron therapy result hemolysis pnh cells pnh chronic condition patients small clone problems monitoring flow cytometry every six months gives information severity risk potential complications given high risk thrombosis pnh preventive treatment warfarin decreases risk thrombosis large clone white blood cells type episodes thrombosis treated would patients given pnh persisting underlying cause likely treatment warfarin similar drugs needs continued longterm episode drug eculizumab approved treatment pnh prior eculizumab median life expectancy individual pnh approximately years since time short midterm studies patients eculizumab demonstrate drug returns patient normal life expectancy improves quality life decreases need blood eculizumab controversial due high cost among expensive pharmaceuticals world price per person per eculizumab humanized monoclonal antibody acts terminal complement inhibitor drug interferes formation membrane attack complex erythrocytes binding compensating loss protective function results deficiency alleviates primary source intravascular hemolysis reduce opsonization erythrocytes caused deficiency patients receive medication often still experience mild moderate us food drug administration fda issued blackbox warning take medication greater risk invasive meningococcal disease people eculizumab strongly advised receive meningococcal vaccination least two weeks prior starting therapy consider preventative antibiotics duration pegcetacoplan approved medical use united states may iptacopan developed novartis possible treatment though large trials taken place pnh rare annual rate cases per prognosis without diseasemodifying treatment many cases develop people previously diagnosed myelodysplastic syndrome fact pnh develops mds also explains appears higher rate leukemia pnh mds sometimes transform leukemia aplastic female cases pnh discovered pregnancy group high rate thrombosis risk death mother child significantly increased first description paroxysmal hemoglobinuria german physician paul str√ºbing greifswald lecture later published later comprehensive descriptions made ettore marchiafava alessio nazari elaborations marchiafava ferdinando micheli dutch physician enneking coined term paroxysmal nocturnal hemoglobinuria haemoglobinuria paroxysmalis nocturna latin since become default peripheral purine nucleoside phosphorylase deficiency httpsenwikipediaorgwikiparoxysmalnocturnalhemoglobinuria